Emory University
Q&A: AI in diabetes care poses many challenges, benefits to patients and clinicians
AI in diabetes care is becoming more popular with various potential benefits for patients and clinicians as well as important challenges to keep in mind, according to a conversation between two diabetes experts.
VIDEO: Important to not ‘exacerbate’ existing disparities with AI
ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the importance of not worsening disparities with the implementation of AI in diabetes care.
VIDEO: The role of clinicians, stakeholders for AI in diabetes
ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about important considerations for using AI in clinical practice.
VIDEO: AI poses potential benefits, challenges in diabetes care
ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the benefits and challenges of using AI in diabetes care.
TIGHT: Inpatient CGM use did not improve glycemic control
ORLANDO — Adding continuous glucose monitoring to hospital standard of care does not appear to improve glycemic control for adults with type 2 diabetes, according to results of the TIGHT study.
‘Our understanding continues to evolve’: HDL cholesterol as a biomarker or risk-enhancer
PHILADELPHIA — HDL cholesterol has not been shown to have a causal role in atherosclerotic cardiovascular disease, nor has lowering it reduced CV outcomes, but it may serve as a marker for CVD risk, according to a speaker.
VIDEO: Healio, COSMO honor Oncology Brothers with Social Media Influencer award
CHICAGO — In partnership with COSMO, Healio awarded the Social Media Influencer award for 2024 to the Oncology Brothers.
Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer
CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Close follow-up, education critical for preventing recurrence of hyperglycemic crises
NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.